FTC Requires Divestitures In Barr, Pliva Merger
Concerned over the anti-competitive effects of Barr Pharmaceutical Inc.'s $2.5 billion acquisition of European generic drug giant Pliva, the U.S. Federal Trade Commission has forced Barr to sell the rights to...To view the full article, register now.
Already a subscriber? Click here to view full article